子宫浆液性癌的靶向治疗：子宫内膜癌的一种侵袭性亚型
Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer.
作者信息
Black Jonathan D, English Diana P, Roque Dana M, Santin Alessandro D
机构信息
Yale University School of Medicine, Department of Obstetrics, Gynecology & Reproductive Sciences, Room 305 Laboratory for Surgery, Obstetrics & Gynecology, 333 Cedar Street; PO Box 208063, New Haven, CT 06520-8063, USA.
出版信息
Womens Health (Lond). 2014 Jan;10(1):45-57. doi: 10.2217/whe.13.72.
Abstract
Uterine serous carcinoma (USC) is a highly aggressive variant of endometrial cancer. Although it only represents less than 10% of all cases, it accounts for a disproportionate number of deaths from endometrial cancer. Comprehensive surgical staging followed by carboplatin and paclitaxel chemotherapy represents the mainstay of USC therapy. Vaginal cuff brachytherapy is also of potential benefit in USC. Recent whole-exome sequencing studies have demonstrated gain of function of the HER2/NEU gene, as well as driver mutations in the PIK3CA/AKT/mTOR and cyclin E/FBXW7 oncogenic pathways in a large number of USCs. These results emphasize the relevance of these novel therapeutic targets for biologic therapy of chemotherapy-resistant recurrent USC.
摘要
子宫浆液性癌（USC）是子宫内膜癌的一种高度侵袭性变体。尽管它仅占所有病例的不到10%，但在子宫内膜癌导致的死亡中却占了相当大的比例。全面的手术分期，随后进行卡铂和紫杉醇化疗是USC治疗的主要手段。阴道残端近距离放射治疗对USC也可能有益。最近的全外显子测序研究表明，在大量的USC中，HER2/NEU基因功能获得，以及PIK3CA/AKT/mTOR和细胞周期蛋白E/FBXW7致癌途径中的驱动突变。这些结果强调了这些新的治疗靶点对于化疗耐药性复发性USC生物治疗的相关性。
相似文献
1
Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer.子宫浆液性癌的靶向治疗：子宫内膜癌的一种侵袭性亚型
Womens Health (Lond). 2014 Jan;10(1):45-57. doi: 10.2217/whe.13.72.
2
Novel targeted therapies in uterine serous carcinoma, an aggressive variant of endometrial cancer.子宫浆液性癌（子宫内膜癌的一种侵袭性变体）的新型靶向治疗
Discov Med. 2016 Apr;21(116):293-303.
3
PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas.PIK3CA致癌突变是HER2/neu过表达的子宫浆液性癌对曲妥珠单抗耐药的主要机制。
Br J Cancer. 2015 Sep 29;113(7):1020-6. doi: 10.1038/bjc.2015.306. Epub 2015 Sep 1.
4
Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo.双重HER2/PIK3CA靶向克服HER2扩增的子宫浆液性癌细胞系在体外和体内的单药获得性耐药
Mol Cancer Ther. 2015 Nov;14(11):2519-26. doi: 10.1158/1535-7163.MCT-15-0383. Epub 2015 Sep 2.
5
SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression.SYD985，一种新型的基于多卡霉素的靶向HER2的抗体药物偶联物，在表达HER2/Neu的子宫浆液性癌中显示出抗肿瘤活性。
Mol Cancer Ther. 2016 Aug;15(8):1900-9. doi: 10.1158/1535-7163.MCT-16-0163. Epub 2016 Jun 2.
6
Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo.在体外和体内，双重靶向CCNE1/PIK3CA对CCNE1扩增/PIK3CA突变的子宫浆液性癌具有协同作用。
Br J Cancer. 2016 Jul 26;115(3):303-11. doi: 10.1038/bjc.2016.198. Epub 2016 Jun 28.
7
Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2).致癌性 PIK3CA 基因突变和 HER2/neu 基因扩增决定了子宫浆液性癌细胞系对 GDC-0980（一种选择性的 I 类 PI3 激酶和 mTOR 激酶（TORC1/2）抑制剂）的敏感性。
Am J Obstet Gynecol. 2013 Nov;209(5):465.e1-9. doi: 10.1016/j.ajog.2013.07.020. Epub 2013 Jul 24.
8
Development of targeted therapy in uterine serous carcinoma, a biologically aggressive variant of endometrial cancer.子宫浆液性癌是子宫内膜癌的一种生物学侵袭性变体，针对其的靶向治疗的发展。
Expert Rev Anticancer Ther. 2012 Jan;12(1):41-9. doi: 10.1586/era.11.192.
9
Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer.BET 溴结构域蛋白抑制剂 GS-5829 和 GS-626510 在子宫内膜癌的一种侵袭性生物变体——子宫浆液性癌中的应用。
Clin Cancer Res. 2018 Oct 1;24(19):4845-4853. doi: 10.1158/1078-0432.CCR-18-0864. Epub 2018 Jun 25.
10
Molecular alterations of EGFR and PIK3CA in uterine serous carcinoma.子宫浆液性癌中EGFR和PIK3CA的分子改变
Gynecol Oncol. 2009 Jun;113(3):370-3. doi: 10.1016/j.ygyno.2008.12.021. Epub 2009 Mar 9.
引用本文的文献
1
Enhancing the therapeutic potential of FDA-approved ifosfamide and 5-fluorouracil through rational chemical modifications for endometrial cancer treatment.通过合理的化学修饰提高美国食品药品监督管理局批准的异环磷酰胺和5-氟尿嘧啶治疗子宫内膜癌的潜力。
Med Oncol. 2025 Jun 25;42(8):281. doi: 10.1007/s12032-025-02821-2.
2
Preclinical Activity of Datopotamab Deruxtecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2, in Uterine Serous Carcinoma.靶向滋养层细胞表面抗原2的抗体药物偶联物达波妥单抗德鲁替康在子宫浆液性癌中的临床前活性
Cancer Res Commun. 2025 May 1;5(5):774-782. doi: 10.1158/2767-9764.CRC-25-0057.
3
Ryanodine receptor 1-mediated Ca signaling and mitochondrial reprogramming modulate uterine serous cancer malignant phenotypes.Ryanodine 受体 1 介导的 Ca 信号转导和线粒体重编程调节子宫浆液性癌恶性表型。
J Exp Clin Cancer Res. 2022 Aug 11;41(1):242. doi: 10.1186/s13046-022-02419-w.
4
Educational Case: Endometrial carcinoma types I and II.教学案例：I型和II型子宫内膜癌
Acad Pathol. 2022 May 17;9(1):100023. doi: 10.1016/j.acpath.2022.100023. eCollection 2022.
5
Evaluating the transcriptional fidelity of cancer models.评估癌症模型的转录保真度。
Genome Med. 2021 Apr 29;13(1):73. doi: 10.1186/s13073-021-00888-w.
6
A 4-gene signature predicts prognosis of uterine serous carcinoma.一个四基因标志物可预测子宫浆液性癌的预后。
BMC Cancer. 2021 Feb 12;21(1):154. doi: 10.1186/s12885-021-07834-4.
7
Kinome Profiling of Primary Endometrial Tumors Using Multiplexed Inhibitor Beads and Mass Spectrometry Identifies SRPK1 as Candidate Therapeutic Target.采用多重抑制剂珠和质谱技术对原发性子宫内膜肿瘤的激酶组进行分析，鉴定出 SRPK1 是候选治疗靶点。
Mol Cell Proteomics. 2020 Dec;19(12):2068-2090. doi: 10.1074/mcp.RA120.002012. Epub 2020 Sep 29.
8
The Role of Eicosanoids in Gynecological Malignancies.类花生酸在妇科恶性肿瘤中的作用。
Front Pharmacol. 2020 Aug 26;11:1233. doi: 10.3389/fphar.2020.01233. eCollection 2020.
9
Prophylactic bilateral Salpingo-oophorectomy and eventual development of endometrial cancer: Two individual case reports.预防性双侧输卵管卵巢切除术与子宫内膜癌的最终发生：两例个案报告。
Case Rep Womens Health. 2020 Mar 26;26:e00195. doi: 10.1016/j.crwh.2020.e00195. eCollection 2020 Apr.
10
Pathogenesis and Clinical Management of Uterine Serous Carcinoma.子宫浆液性癌的发病机制与临床管理
Cancers (Basel). 2020 Mar 14;12(3):686. doi: 10.3390/cancers12030686.
本文引用的文献
1
Targeting proteasomal pathways by dietary curcumin for cancer prevention and treatment.通过膳食姜黄素靶向蛋白酶体途径预防和治疗癌症。
Curr Med Chem. 2014;21(14):1583-94. doi: 10.2174/09298673113206660135.
2
Expression of cyclin A, cyclin E and p27 in normal, hyperplastic and frankly malignant endometrial samples.细胞周期蛋白A、细胞周期蛋白E和p27在正常、增生性及明显恶性子宫内膜样本中的表达
J Obstet Gynaecol. 2013 Jul;33(5):508-11. doi: 10.3109/01443615.2013.776024.
3
Anti-angiogenic drugs currently in Phase II clinical trials for gynecological cancer treatment.目前处于妇科癌症治疗二期临床试验的抗血管生成药物。
Expert Opin Investig Drugs. 2013 Sep;22(9):1181-92. doi: 10.1517/13543784.2013.812071. Epub 2013 Jun 20.
4
Tubulin-β-III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones.子宫浆液性癌中微管蛋白-β-III 的过表达是铂类/紫杉烷化疗后总生存期不良的标志物，并且对埃坡霉素类药物敏感。
Cancer. 2013 Jul 15;119(14):2582-92. doi: 10.1002/cncr.28017. Epub 2013 Apr 12.
5
Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone.III 类β-微管蛋白在卵巢透明细胞癌和浆液性癌中的过表达是铂类/紫杉烷化疗后总生存不良的标志物，以及对帕妥珠单抗敏感的标志物。
Am J Obstet Gynecol. 2013 Jul;209(1):62.e1-9. doi: 10.1016/j.ajog.2013.04.017. Epub 2013 Apr 10.
6
High phospho-Stathmin(Serine38) expression identifies aggressive endometrial cancer and suggests an association with PI3K inhibition.高磷酸化 Stathmin（丝氨酸 38 位）表达鉴定侵袭性子宫内膜癌，并提示与 PI3K 抑制相关。
Clin Cancer Res. 2013 May 1;19(9):2331-41. doi: 10.1158/1078-0432.CCR-12-3413. Epub 2013 Mar 28.
7
HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies.HER2 表达超出乳腺癌：妇科恶性肿瘤的治疗意义。
Mol Diagn Ther. 2013 Apr;17(2):85-99. doi: 10.1007/s40291-013-0024-9.
8
Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer.曲妥珠单抗-美坦新偶联物（T-DM1）用于治疗 HER2 阳性乳腺癌。
Curr Med Res Opin. 2013 Apr;29(4):405-14. doi: 10.1185/03007995.2013.775113. Epub 2013 Mar 1.
9
Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma.子宫浆液性癌中体细胞单核苷酸和拷贝数突变的全景
Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):2916-21. doi: 10.1073/pnas.1222577110. Epub 2013 Jan 28.
10
A novel cyclinE/cyclinA-CDK inhibitor targets p27(Kip1) degradation, cell cycle progression and cell survival: implications in cancer therapy.一种新型细胞周期蛋白 E/细胞周期蛋白 A-CDK 抑制剂靶向 p27(Kip1)降解、细胞周期进程和细胞存活：对癌症治疗的影响。
Cancer Lett. 2013 Jun 1;333(1):103-12. doi: 10.1016/j.canlet.2013.01.025. Epub 2013 Jan 24.
Zotero 插件